Lenvatinib administered to patients with unresectable HCC who were unresponsive to PD-1/PD-L1 checkpoint blockade demonstrated considerable antitumor activity and a tolerable safety profile. This evidence concerns the gene CD274 and hepatocellular carcinoma.